Status:
UNKNOWN
Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Helicobacter Pylori Infection
Intravenous Drug Usage
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Helicobacter pylori infection causes active peptic ulcer disease and related complications like bleeding and pyloric obstruction. Usually, clinicians tended to treat Helicobacter pylori infection afte...
Eligibility Criteria
Inclusion
- Male or female aged between 18 and 75 years old
- Without previous Helicobacter pylori treatment
- Diagnosed with active peptic ulcer disease and related complications like bleeding and pyloric obstruction by endoscopy examination
- Ability and willingness to participate in the study and to sign and give informed consent
- Positive for Helicobacter pylori IgM antibody
Exclusion
- With previous gastric surgery
- Major systemic diseases
- Pregnancy or lactation
- Allergy to any of the study drugs
- Decline to participate in the study
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 15 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04432233
Start Date
June 15 2020
End Date
June 15 2021
Last Update
August 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200127